Success Metrics

Completion Rate
0%(0/2)
Active Trials
2(33%)
Terminated
2(33%)

Phase Distribution

Ph phase_1
2
33%
Ph phase_2
4
67%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Terminated(4)

Detailed Status

Withdrawn2
Terminated2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

recruiting117%
active_not_recruiting117%
withdrawn233%
terminated233%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_2

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

NCT06449313
active_not_recruitingphase_1

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

NCT04975152
terminatedphase_2

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

NCT04006119
withdrawnphase_1

Cemiplimab/Peg-Interferon-α in Advanced CSCC

NCT05729139
terminatedphase_2

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

NCT04242173
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06449313Phase 2

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Recruiting
NCT04975152Phase 1

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Active Not Recruiting
NCT04006119Phase 2

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Terminated
NCT05729139Phase 1

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Withdrawn
NCT04242173Phase 2

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Terminated
NCT04831450Phase 2

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6